Aurobindo, Glenmark, Natco secure USFDA approval for migraine tablets
The three Indian drug firms have secured approvals from USFDA to launch their migraine drugs in the US market.
Hyderabad, July 3, 2013: The Indian drugmakers Aurobindo Pharma, Natco Pharma and Glenmark have announced obtaining approvals from the US Food and Drug Administration (USFDA) to launch their migraine drugs in the US market. It may be noted here that Aurobindo, Natco and Glenmark are among 8-9 global pharmaceutical companies that received FDA approval for Rizatriptan Benzoate orally disintegrating tablets (ODT), generic equivalents of Merck & Co Inc's Maxalt-MLT, for use in adults and paediatric patients of 6-17 years.
Going by the IMS Health data, the annual sales of the product during the year ended April 2013 amounted to US$ 271 million or Rs 1,616 crore.
Natco Pharma said in a statement that the drug shipments were already made and the product is being marketed by its partner Breckenridge Pharmaceuticals in the US market.